Skip to main
BMY

Bristol-Myers (BMY) Stock Forecast & Price Target

Bristol-Myers (BMY) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 21%
Buy 21%
Hold 50%
Sell 7%
Strong Sell 0%

Bulls say

Bristol-Myers Squibb is expected to have strong total revenue growth in the coming years, with estimated total revenue of $46,990M, $45,614M, and $40,649M for 2026, 2027, and 2028, respectively. This is driven by their strong focus on immuno-oncology, where they are a leader in drug development, and their continued success in the US market, which accounts for 70% of their total sales. Additionally, the increase in their price target is supported by an increasing exit multiple in their DCF analysis, showing potential for strong future financial performance.

Bears say

Bristol-Myers Squibb is heavily dependent on the US market, which poses a risk of revenue concentration. There is potential for transformative clinical readouts in various therapeutic areas, but there are still fundamental risks such as increased competition and potential for delays in clinical trials. The company's recent guidance updates show conservative sales growth for their popular drug Eliquis and increased PoS for their other drugs, resulting in a higher price target of $72/share.

Bristol-Myers (BMY) has been analyzed by 14 analysts, with a consensus rating of Buy. 21% of analysts recommend a Strong Buy, 21% recommend Buy, 50% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bristol-Myers and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bristol-Myers (BMY) Forecast

Analysts have given Bristol-Myers (BMY) a Buy based on their latest research and market trends.

According to 14 analysts, Bristol-Myers (BMY) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $61.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $61.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bristol-Myers (BMY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.